间歇烷化剂化疗逆转转移性黑色素瘤原发免疫检查点抑制剂耐药:多中心II期试验结果
PROMIT试验纳入53例BRAF野生型转移性黑色素瘤原发ICI耐药患者,其中38例可评估疗效。给予两剂达卡巴嗪850 mg/m²后原ICI方案再挑战,客观缓解率18%(95%CI 0.08-0.34),7例部分缓解,疾病控制率37%。治疗耐受良好,≥3级治疗相关不良事件发生率10%,未见新安全信号。
要点
- 短程达卡巴嗪后ICI再挑战可使部分原发耐药黑色素瘤患者获益。
- 客观缓解率18%,7/38例达部分缓解,疾病控制率37%。
- ≥3级治疗相关不良事件发生率10%,耐受性良好。
核心结论
- 短期烷化剂化疗后ICI再挑战可克服部分黑色素瘤患者的原发ICI耐药。
研究设计与样本
- PROMIT(NCT04225390)为前瞻性多中心II期试验,在德国4家皮肤肿瘤中心纳入53例组织学确诊的BRAF野生型转移性黑色素瘤原发ICI耐药患者。
- 38例可评估疗效,定义为至少接受一次ICI再暴露。
- 达卡巴嗪850 mg/m²静脉给药,第1天和第21天各一次,第二剂后1周以原ICI方案再挑战。
主要发现
- 总体客观缓解率为18%(95%CI 0.08-0.34),38例中7例达部分缓解。
- 疾病控制率为37%。
- 治疗耐受良好,治疗相关≥3级CTCAE不良事件发生率为10%,未见新安全信号。
临床怎么用
- 对BRAF野生型转移性黑色素瘤原发ICI耐药患者,短程达卡巴嗪后原ICI再挑战可作为潜在治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with BRAF wildtype metastatic melanoma who exhibit primary resistance to immune checkpoint inhibitors (ICIs) have a poor prognosis. Chemotherapy has been shown to induce genetic mutations, modify the tumour microenvironment and microbiome, and influence immune system activity. OBJECTIVES: To investigate in a prospective multicentre phase II trial whether two applications of an alkylating agent (dacarbazine) can sensitize patients with metastatic melanoma who are nonresponsive to ICIs to the same checkpoint inhibitor regime. METHODS: The PROMIT trial (NCT04225390) enrolled patients with histologically confirmed BRAF wildtype metastatic melanoma who exhibited primary resistance to ICI therapy. Following radiological evidence of primary resistance to ICI (ipilimumab + nivolumab or pembrolizumab) upon the first staging after initiation, patients received two doses of dacarbazine at 850 mg m-2 intravenously on days 1 and 21. Subsequently, 1 week after application of the second dose of dacarbazine, patients were rechallenged with the same ICI therapy to which they had previously shown progressive disease. RESULTS: In total, 53 patients were enrolled across four German skin cancer centres. Of these patients, 38 were evaluable for efficacy, having received at least one dose of ICI re-exposure. The overall objective response rate was 18% (95% confidence interval 0.08-0.34), with 7 of 38 patients achieving a partial response. The disease control rate was 37%. Therapy was well tolerated, with treatment-related ≥ grade 3 CTCAE adverse events occurring in 10% of patients. No new safety signals were observed. CONCLUSIONS: The study indicates that short-term chemotherapy followed by ICI rechallenge can overcome primary ICI resistance in patients with melanoma, supporting its potential as a new therapeutic option in clinical practice. Metastatic melanoma is a serious and aggressive form of skin cancer. It can spread to other parts of the body. Mutations in some genes (part of our DNA) can result in melanoma. One of these genes is called ‘BRAF’. The treatment options are limited for patients whose melanoma does not have a mutation in the BRAF gene and who do not benefit from a type of therapy called ‘immune checkpoint inhibitors’ (ICIs). In this study, we aimed to find out whether a short course of chemotherapy could help these patients with melanoma benefit from ICI therapy. The study took place at four skin cancer centres in Germany. It included 38 patients with metastatic melanoma who had not responded to ICI treatment before. The patients received two doses of a chemotherapy drug called ‘dacarbazine’. After this, they were treated again with the same ICI therapy that had previously not helped them. The aim was to see if this approach could improve their chances of benefiting from ICI treatment. The tumours shrank in 7 of the 38 patients. This is a result known as a ‘partial response’. The cancer either shrank or stopped growing in 14 patients. The treatment was generally well tolerated. Serious side effects related to the treatment occurred in 17 patients (10%), but no unexpected safety concerns were reported. These findings suggest that a short course of chemotherapy may help some patients overcome resistance to immunotherapy. This approach could provide a new option for patients with melanoma who have limited treatment choices.
引用
- Haferkamp S, Schilling B, Berking C, et al. Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial. Br J Dermatol. 2026. PMID: 40905153. doi:10.1093/bjd/ljaf350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。